+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Nucleic Acid Therapeutics CDMO Market by Therapeutics Type (DNA Therapeutics, RNA Therapeutics), Service Type (Analytical Testing & Quality Control, Manufacturing, Packaging & Distribution), Therapeutic Applications, End User - Global Forecast 2025-2030- Product Image
Nucleic Acid Therapeutics CDMO Market by Therapeutics Type (DNA Therapeutics, RNA Therapeutics), Service Type (Analytical Testing & Quality Control, Manufacturing, Packaging & Distribution), Therapeutic Applications, End User - Global Forecast 2025-2030- Product Image
Sale

Nucleic Acid Therapeutics CDMO Market by Therapeutics Type (DNA Therapeutics, RNA Therapeutics), Service Type (Analytical Testing & Quality Control, Manufacturing, Packaging & Distribution), Therapeutic Applications, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 196 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6013697
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Nucleic Acid Therapeutics CDMO Market is navigating a pivotal phase, where specialized contract development and manufacturing services (CDMOs) are enabling the rapid commercialization of next-generation biopharmaceuticals. Senior decision-makers face an evolving landscape shaped by technology, regulatory demands, and new production paradigms.

Market Snapshot: Nucleic Acid Therapeutics CDMO Market Growth

The Nucleic Acid Therapeutics CDMO Market grew from USD 10.77 billion in 2024 to USD 12.00 billion in 2025. It is expected to continue growing at a CAGR of 11.42%, reaching USD 20.62 billion by 2030. This growth trajectory reflects robust demand as DNA and RNA therapeutics gain momentum and manufacturers invest in enabling technologies, scalable processes, and resilient global supply chains.

Scope & Segmentation

This research provides comprehensive insight into pivotal dimensions across the market landscape. Segmentation is designed to support senior executives in strategic planning, market entry, and partnership decisions.

  • Therapeutics Type: DNA Therapeutics, RNA Therapeutics
  • Service Type: Analytical Testing & Quality Control, Manufacturing, Packaging & Distribution, Process Development & Optimization
  • Therapeutic Applications: Genetic Disorders, Infectious Diseases, Neurological Disorders, Oncology, Rare Disorders
  • End User: Academic & Research Institutes, Biotechnology Firms, Pharmaceutical Companies
  • Regional Coverage: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe Middle East & Africa (covering United Kingdom, Germany, France, Russia, Italy, Spain, UAE, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (including China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Technology Advances: Synthetic gene synthesis, lipid nanoparticle delivery, process intensification, microfluidic encapsulation, continuous bioprocessing, modular facility design, digital analytics, and machine learning integration

Key market players assessed include AGC Biologics Inc., Agilent Technologies, Inc., Ajinomoto Bio-Pharma Services, Almac Group Ltd., Biomay AG, BioSpring GmbH, Catalent, Inc., Charles River Laboratories International, Inc., and others.

Key Takeaways for Senior Decision-Makers

  • Specialized CDMO partnerships play a critical role in expediting the transition of nucleic acid therapeutics from early-stage development to clinical and commercial manufacturing.
  • Technological innovation—including microfluidic and digital process enhancements—is unlocking rapid, quality-driven scale-up and greater operational flexibility.
  • Service differentiation is achieved through integrated offerings that cover analytical, manufacturing, and distribution needs while ensuring regulatory compliance.
  • Collaboration between CDMOs, equipment suppliers, and pharma innovators catalyzes faster technology transfer and supports tailored solutions for complex modalities.
  • Geographic strategy is essential to leverage local talent, regulatory environments, and supply chain resilience, enabling greater competitiveness across regions.
  • Sustainability initiatives, such as green chemistry and resource-efficient facility operations, are increasingly essential for long-term stakeholder confidence and cost optimization.

Tariff Impact: Adjustments Shaping Supply Chain Strategies

Recent changes in United States tariffs on raw materials and reagents are prompting realignment in CDMO sourcing models. Dual-sourcing, regional warehousing, and stronger domestic capabilities are mitigating delays and input cost volatility. Long-term vendor agreements and collaborative ventures with chemical producers offer price stability and secure access in a dynamic trade environment. These measures have led to reevaluation of global operational footprints for enhanced supply chain resilience.

Methodology & Data Sources

This report utilizes a multi-phase methodology combining secondary research from peer-reviewed publications, patent databases, regulatory filings, and industry white papers with primary interviews of senior executives and technical experts. Analytical tools such as SWOT analysis, value-chain mapping, and scenario modeling have been used to validate findings and provide strategic clarity.

Nucleic Acid Therapeutics CDMO Market: Why This Report Matters

  • Empowers senior leaders with a clear understanding of the evolving CDMO landscape, enabling informed partnership and investment decisions.
  • Delivers actionable insights into service differentiation, technology adoption, regulatory navigation, and supply chain fortification for future growth.
  • Provides a rigorous, segmented view for better alignment with clinical, operational, and geographic priorities.

Conclusion

The Nucleic Acid Therapeutics CDMO Market is advancing with new service models, technology integrations, and geographic agility. Equipped with this research, decision-makers can confidently set strategies that align capabilities with evolving market opportunities and operational requirements for sustainable growth.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising demand for scalable mRNA production platforms with optimized lipid nanoparticle formulation capabilities
5.2. Integration of automated high-throughput screening in oligonucleotide manufacturing workflows to accelerate process development
5.3. Adoption of continuous manufacturing for plasmid DNA to enhance yield consistency and reduce contamination risk
5.4. Strategic partnerships between CDMOs and biotech firms for co-development of gene editing therapies using CRISPR-Cas systems
5.5. Investment in modular single-use bioreactor systems tailored for viral vector production to support gene therapy pipelines
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Nucleic Acid Therapeutics CDMO Market, by Therapeutics Type
8.1. Introduction
8.2. DNA Therapeutics
8.3. RNA Therapeutics
9. Nucleic Acid Therapeutics CDMO Market, by Service Type
9.1. Introduction
9.2. Analytical Testing & Quality Control
9.3. Manufacturing
9.4. Packaging & Distribution
9.5. Process Development & Optimization
10. Nucleic Acid Therapeutics CDMO Market, by Therapeutic Applications
10.1. Introduction
10.2. Genetic Disorders
10.3. Infectious Diseases
10.4. Neurological Disorders
10.5. Oncology
10.6. Rare Disorders
11. Nucleic Acid Therapeutics CDMO Market, by End User
11.1. Introduction
11.2. Academic & Research Institutes
11.3. Biotechnology Firms
11.4. Pharmaceutical Companies
12. Americas Nucleic Acid Therapeutics CDMO Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Nucleic Acid Therapeutics CDMO Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Nucleic Acid Therapeutics CDMO Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. AGC Biologics Inc.
15.3.2. Agilent Technologies, Inc.
15.3.3. Ajinomoto Bio-Pharma Services
15.3.4. Almac Group Ltd.
15.3.5. Biomay AG
15.3.6. BioSpring GmbH
15.3.7. Catalent, Inc.
15.3.8. Charles River Laboratories International, Inc.
15.3.9. CordenPharma International GmbH
15.3.10. Creative Biogene
15.3.11. Danaher Corporation
15.3.12. Eurofins Scientific SE
15.3.13. Evonik Industries AG
15.3.14. GenScript Biotech Corporation
15.3.15. Lonza Group Ltd.
15.3.16. Polypeptide Group AG
15.3.17. Recipharm AB
15.3.18. Rentschler Biopharma SE
15.3.19. Samsung Biologics
15.3.20. The Scripps Research Institute
15.3.21. Touchlight Group
15.3.22. Univercells Group
15.3.23. WuXi AppTec Co., Ltd.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. NUCLEIC ACID THERAPEUTICS CDMO MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. NUCLEIC ACID THERAPEUTICS CDMO MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. NUCLEIC ACID THERAPEUTICS CDMO MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. NUCLEIC ACID THERAPEUTICS CDMO MARKET: RESEARCHAI
FIGURE 24. NUCLEIC ACID THERAPEUTICS CDMO MARKET: RESEARCHSTATISTICS
FIGURE 25. NUCLEIC ACID THERAPEUTICS CDMO MARKET: RESEARCHCONTACTS
FIGURE 26. NUCLEIC ACID THERAPEUTICS CDMO MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. NUCLEIC ACID THERAPEUTICS CDMO MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY DNA THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY DNA THERAPEUTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RNA THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RNA THERAPEUTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ANALYTICAL TESTING & QUALITY CONTROL, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY MANUFACTURING, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PACKAGING & DISTRIBUTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PACKAGING & DISTRIBUTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT & OPTIMIZATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PROCESS DEVELOPMENT & OPTIMIZATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RARE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY RARE DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
TABLE 46. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2030 (USD MILLION)
TABLE 47. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 48. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 49. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 50. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 55. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
TABLE 56. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2030 (USD MILLION)
TABLE 57. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 58. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 59. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 60. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 61. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 62. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 63. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 64. UNITED STATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 65. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
TABLE 66. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2030 (USD MILLION)
TABLE 67. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 68. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 69. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 70. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 71. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 72. CANADA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 73. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
TABLE 74. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2030 (USD MILLION)
TABLE 75. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 76. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 77. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 78. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 79. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 80. MEXICO NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 81. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
TABLE 82. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2030 (USD MILLION)
TABLE 83. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 84. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 85. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 86. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 87. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 88. BRAZIL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 89. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
TABLE 90. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2030 (USD MILLION)
TABLE 91. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 92. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 93. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 94. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 95. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 96. ARGENTINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
TABLE 108. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 110. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 112. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 114. UNITED KINGDOM NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 115. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
TABLE 116. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2030 (USD MILLION)
TABLE 117. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 118. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 119. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 120. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 121. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 122. GERMANY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 123. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
TABLE 124. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2030 (USD MILLION)
TABLE 125. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 126. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 127. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 128. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 129. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. FRANCE NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
TABLE 132. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2030 (USD MILLION)
TABLE 133. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 134. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 135. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 136. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 137. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 138. RUSSIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 139. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
TABLE 140. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2030 (USD MILLION)
TABLE 141. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 142. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 143. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 144. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 145. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 146. ITALY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 147. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
TABLE 148. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2030 (USD MILLION)
TABLE 149. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 150. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 151. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 152. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 153. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 154. SPAIN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 155. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
TABLE 156. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2030 (USD MILLION)
TABLE 157. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 158. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 159. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 160. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 161. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 162. UNITED ARAB EMIRATES NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
TABLE 164. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2030 (USD MILLION)
TABLE 165. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 166. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 167. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 168. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 169. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. SAUDI ARABIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
TABLE 172. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2030 (USD MILLION)
TABLE 173. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 174. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 175. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 176. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 177. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 178. SOUTH AFRICA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 179. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
TABLE 180. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2030 (USD MILLION)
TABLE 181. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 182. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 183. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 184. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 185. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 186. DENMARK NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 187. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
TABLE 188. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2030 (USD MILLION)
TABLE 189. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 190. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 191. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 192. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 193. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 194. NETHERLANDS NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 195. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
TABLE 196. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2030 (USD MILLION)
TABLE 197. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 198. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 199. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 200. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 201. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 202. QATAR NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 203. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
TABLE 204. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2030 (USD MILLION)
TABLE 205. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 206. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 207. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 208. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 209. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. FINLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
TABLE 212. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2030 (USD MILLION)
TABLE 213. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 214. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 215. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 216. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 217. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. SWEDEN NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
TABLE 220. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2030 (USD MILLION)
TABLE 221. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 222. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 223. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 224. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 225. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 226. NIGERIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 227. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
TABLE 228. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2030 (USD MILLION)
TABLE 229. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 230. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 231. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 232. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 233. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 234. EGYPT NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 235. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
TABLE 236. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2030 (USD MILLION)
TABLE 237. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 238. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 239. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 240. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 241. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 242. TURKEY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 243. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
TABLE 244. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2030 (USD MILLION)
TABLE 245. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 246. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 247. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 248. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 249. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 250. ISRAEL NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 251. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
TABLE 252. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2030 (USD MILLION)
TABLE 253. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 254. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 255. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 256. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 257. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 258. NORWAY NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 259. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
TABLE 260. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2030 (USD MILLION)
TABLE 261. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 262. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 263. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 264. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 265. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. POLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
TABLE 268. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2030 (USD MILLION)
TABLE 269. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 270. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 271. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 272. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 273. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 274. SWITZERLAND NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 275. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
TABLE 276. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2030 (USD MILLION)
TABLE 277. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 278. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 279. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 280. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 281. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 282. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 283. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 284. ASIA-PACIFIC NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 285. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
TABLE 286. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2030 (USD MILLION)
TABLE 287. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 288. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 289. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 290. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 291. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 292. CHINA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 293. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2018-2024 (USD MILLION)
TABLE 294. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTICS TYPE, 2025-2030 (USD MILLION)
TABLE 295. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 296. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 297. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
TABLE 298. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2030 (USD MILLION)
TABLE 299. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 300. INDIA NUCLEIC ACID THERAPEUTICS CDMO MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 301. JAPAN NUCLEIC ACID T

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Nucleic Acid Therapeutics CDMO market report include:
  • AGC Biologics Inc.
  • Agilent Technologies, Inc.
  • Ajinomoto Bio-Pharma Services
  • Almac Group Ltd.
  • Biomay AG
  • BioSpring GmbH
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • CordenPharma International GmbH
  • Creative Biogene
  • Danaher Corporation
  • Eurofins Scientific SE
  • Evonik Industries AG
  • GenScript Biotech Corporation
  • Lonza Group Ltd.
  • Polypeptide Group AG
  • Recipharm AB
  • Rentschler Biopharma SE
  • Samsung Biologics
  • The Scripps Research Institute
  • Touchlight Group
  • Univercells Group
  • WuXi AppTec Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages196
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 12 Billion
Forecasted Market Value ( USD ) by 2030 $ 20.62 Billion
Compound Annual Growth Rate11.4%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis Report By Type, By Service, By End-use, By Application, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis Report By Type, By Service, By End-use, By Application, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 170 Pages
  • Global
From
Nucleic Acid Therapeutics CDMO - Global Strategic Business Report - Product Image

Nucleic Acid Therapeutics CDMO - Global Strategic Business Report

  • Report
  • 200 Pages
  • Global
From
Peptide and Oligonucleotide CDMO - Global Strategic Business Report - Product Image

Peptide and Oligonucleotide CDMO - Global Strategic Business Report

  • Report
  • 370 Pages
  • Global
From
Peptide and Oligonucleotide CDMO Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Peptide and Oligonucleotide CDMO Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Transfection Technologies Market Report 2025 - Product Image

Transfection Technologies Market Report 2025

  • Report
  • 200 Pages
  • Global
From

About the Nucleic Acid Therapeutics CDMO Market

The Nucleic Acid Therapeutics CDMO market is a subset of the Pharmaceutical Manufacturing industry. It focuses on the production of nucleic acid-based drugs, such as DNA and RNA-based therapeutics, for use in the treatment of various diseases. These drugs are produced using a variety of techniques, including gene therapy, gene editing, and gene silencing. The market is driven by the increasing demand for personalized medicines, as well as the need for more efficient and cost-effective production methods. The Nucleic Acid Therapeutics CDMO market is highly competitive, with a number of companies offering services in the field. These include companies such as Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Moderna Therapeutics. Other companies in the market include Cellectis, CRISPR Therapeutics, and Intellia Therapeutics. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.